722 PHASE-II TRIAL OF COMBINATION TREATMENT OF INTERFERON-ALFA, CIMETIDINE, CYCLOOXYGENASE-2 INHIBITOR AND RENIN-ANGIOTENSIN-SYSTEM INHIBITOR (I-CCA) FOR METASTATIC RENAL CELL CARCINOMA

2011 ◽  
Vol 10 (2) ◽  
pp. 230
Author(s):  
M. Tatokoro ◽  
Y. Fujii ◽  
S. Kawakami ◽  
K. Saito ◽  
F. Koga ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Combination Treatment ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Renin Angiotensin System ◽  
Interferon Alfa ◽  
Angiotensin System

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.

1998 ◽  
Vol 16 (8) ◽  
pp. 2728-2732 ◽  
Author(s):  
A Ravaud ◽  
B Audhuy ◽  
F Gomez ◽  
B Escudier ◽  
T Lesimple ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Renal Carcinoma ◽  
Phase Ii Trial ◽  
Interleukin 2 ◽  
Interferon Alfa

PURPOSE A phase II trial was designed to determine the efficacy and the tolerance of interleukin-2 (IL-2), interferon alfa-2a (IFNalpha), and fluorouracil (5-FU) in patients with metastatic renal cell carcinoma. PATIENTS AND METHODS One hundred eleven patients were included. Patients received subcutaneous IL-2 9 x 10(6) IU daily for 6 days and IFNalpha 6 x 10(6) IU on days 1, 3, and 5 every other week for 8 weeks. 5-FU was administered through a continuous infusion at 600 mg/m2 for 5 consecutive days for 1 week every 4 weeks. RESULTS The response rate was 1.8% (95% confidence interval [CI], 0% to 4.3%) with only two partial responses (PRs). Toxicity was moderate with 3.6% grade 4 events and two deaths related to treatment. CONCLUSION This regimen of IL-2, IFNalpha, and 5-FU in patients with metastatic renal cell carcinoma was ineffective. The results raise the question of the dose and schedule of subcutaneous cytokines that must be used in metastatic renal carcinoma.

Phase II Trial of Low Dose γ -Interferon in Metastatic Renal Cell Carcinoma

1994 ◽  
Vol 152 (3) ◽  
pp. 841-845 ◽  
Author(s):  
Julie A. Ellerhorst ◽  
Robert G. Kilbourn ◽  
Robert J. Amato ◽  
Alexander A. Zukiwski ◽  
Elaine Jones ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Low Dose ◽  
Phase Ii Trial ◽  
Γ Interferon

An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma

2010 ◽  
Vol 66 (6) ◽  
pp. 1065-1070 ◽  
Author(s):  
Seiji Naito ◽  
Taiji Tsukamoto ◽  
Michiyuki Usami ◽  
Hiroyuki Fujimoto ◽  
Hideyuki Akaza
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Early Phase ◽  
Phase Ii Trial ◽  
Japanese Patients

scholarly journals Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma

Urology ◽  
2008 ◽  
Vol 72 (4) ◽  
pp. 898-902 ◽  
Author(s):  
Shanthi Marur ◽  
James Eliason ◽  
Lance K. Heilbrun ◽  
Brenda Dickow ◽  
Daryn W. Smith ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Weekly Docetaxel
Sign in / Sign up

Export Citation Format

Share Document